Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia
BACKGROUND: SARS-CoV-2 pandemic has posed formidable public health and clinical challenges. The use of immunosuppressive agents, such as high dose corticosteroids and cytokine inhibitors (e.g., Tocilizumab) has been suggested to contrast the hyperinflammatory process involved in the pathogenesis of the severe disease, with conflicting evidence. Among the drawbacks of immunosuppressive therapy, the risk of reactivation of latent infections, including parasitic infestations, is to be considered.
CASE PRESENTATION: We report a case of a 59-year-old Italian patient treated with high dose intravenous dexamethasone and two intravenous doses of Tocilizumab for interstitial bilateral pneumonia associated with SARS-CoV-2 infection who developed itching, abdominal pain, and an increased eosinophil count. Stool examination confirmed the presence of S. stercoralis larvae. The patient was treated with a 4-day course of Ivermectin with full recovery.
DISCUSSION: We report the first case of S. stercoralis infection following an 11-day treatment with high-dose steroids and Tocilizumab for severe COVID-19. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19.
| Errataetall: |
CommentIn: Infection. 2021 Oct;49(5):1065-1067. - PMID 33970429 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Infection - 49(2021), 3 vom: 10. Juni, Seite 539-542 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Marchese, Valentina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.06.2021 Date Revised 07.12.2022 published: Print-Electronic CommentIn: Infection. 2021 Oct;49(5):1065-1067. - PMID 33970429 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s15010-020-01522-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314825347 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314825347 | ||
| 003 | DE-627 | ||
| 005 | 20231225153555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-020-01522-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314825347 | ||
| 035 | |a (NLM)32910321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marchese, Valentina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Infection. 2021 Oct;49(5):1065-1067. - PMID 33970429 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: SARS-CoV-2 pandemic has posed formidable public health and clinical challenges. The use of immunosuppressive agents, such as high dose corticosteroids and cytokine inhibitors (e.g., Tocilizumab) has been suggested to contrast the hyperinflammatory process involved in the pathogenesis of the severe disease, with conflicting evidence. Among the drawbacks of immunosuppressive therapy, the risk of reactivation of latent infections, including parasitic infestations, is to be considered | ||
| 520 | |a CASE PRESENTATION: We report a case of a 59-year-old Italian patient treated with high dose intravenous dexamethasone and two intravenous doses of Tocilizumab for interstitial bilateral pneumonia associated with SARS-CoV-2 infection who developed itching, abdominal pain, and an increased eosinophil count. Stool examination confirmed the presence of S. stercoralis larvae. The patient was treated with a 4-day course of Ivermectin with full recovery | ||
| 520 | |a DISCUSSION: We report the first case of S. stercoralis infection following an 11-day treatment with high-dose steroids and Tocilizumab for severe COVID-19. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19 | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunosuppression | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Strongyloides stercoralis | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antiparasitic Agents |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Ivermectin |2 NLM | |
| 650 | 7 | |a 70288-86-7 |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Crosato, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Gulletta, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Castelnuovo, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Cristini, Graziella |e verfasserin |4 aut | |
| 700 | 1 | |a Matteelli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Castelli, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d 1973 |g 49(2021), 3 vom: 10. Juni, Seite 539-542 |w (DE-627)NLM00001740X |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2021 |g number:3 |g day:10 |g month:06 |g pages:539-542 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s15010-020-01522-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2021 |e 3 |b 10 |c 06 |h 539-542 | ||